Shameem M, Katori N, Aoyagi N, Kojima S
Division of Drugs, National Institute of Health Sciences, Tokyo, Japan.
Pharm Res. 1995 Jul;12(7):1049-54. doi: 10.1023/a:1016270701021.
This study was undertaken to examine the effects of mechanical destructive forces on drug release from controlled release (CR) dosage forms in vitro and in vivo and their colonic release, using two CR tablets of acetaminophen A and B, showing slower and faster erosion rates, respectively.
In vitro release rates were determined by several official methods. Tablets were administered to healthy volunteers under fasting and fed conditions.
Both tablets showed similar release rates under mild destructive conditions (e.g., paddle method at 10 rpm) but CR-B showed faster release under highly destructive conditions (e.g., rotating basket method at 150 rpm), where the tablet was eroded. The in vivo release from CR-B was faster than from CR-A, possibly because of enhanced erosion. The variable in vivo release from CR-B indicated large inter-subject differences in destructive GI forces. The fastest in vivo release from CR-B among individuals was approximated by the in vitro dissolution determined by destructive methods such as the rotating basket at 150 rpm. The slowest in vivo release from tablets A and B was lower than the dissolution by the paddle method at 10 rpm. The release from both tablets was markedly reduced at 3-4 hrs after dosing irrespective of feeding conditions which can be attributed to release inhibition in the colon.
Effects of GI destructive forces on the tablet erosion and the release inhibition in the colon must be considered in the development of CR dosage forms.
本研究旨在使用对乙酰氨基酚的两种控释(CR)片剂A和B,分别显示出较慢和较快的侵蚀速率,来研究机械破坏力对控释剂型体外和体内药物释放及其结肠释放的影响。
通过几种官方方法测定体外释放速率。在空腹和进食条件下将片剂给予健康志愿者。
在温和的破坏条件下(例如,10转/分钟的桨法),两种片剂显示出相似的释放速率,但在高度破坏条件下(例如,150转/分钟的旋转篮法),片剂被侵蚀时,CR-B显示出更快的释放。CR-B的体内释放比CR-A更快,这可能是由于侵蚀增强。CR-B体内释放的变化表明受试者间胃肠道破坏力存在很大差异。个体中CR-B最快的体内释放可通过150转/分钟旋转篮等破坏方法测定的体外溶出度来近似。片剂A和B最慢的体内释放低于10转/分钟桨法的溶出度。给药后3 - 4小时,无论进食条件如何,两种片剂的释放均显著降低,这可归因于结肠中的释放抑制。
在控释剂型的开发中,必须考虑胃肠道破坏力对片剂侵蚀和结肠中释放抑制的影响。